Related Experiment Video
Updated: May 14, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Association between preprocedural hemoglobin level and 1-year outcome of elective percutaneous coronary intervention
Seyed Kianoosh Hosseini1, Mohammad Javad Alemzadeh Ansari, Masoumeh Lotfi Tokaldany
1aTehran Heart Center, Interventional Cardiology Department,Tehran University of Medical Sciences bTehran Heart Center, Research Department, Tehran University of Medical Sciences, Tehran, Iran.
Insights
Severe anemia (hemoglobin < 10 g/dL) significantly increases the risk of major adverse cardiac events (MACE) within one year after percutaneous coronary intervention (PCI). This highlights the importance of monitoring hemoglobin levels in patients undergoing PCI.
Area of Science:
- Cardiology
- Hematology
Background:
- Anemia is a common comorbidity in patients undergoing percutaneous coronary intervention (PCI).
- The association between preprocedural hemoglobin (Hb) levels and adverse cardiac outcomes post-PCI requires further elucidation.
Purpose of the Study:
- To investigate the relationship between preprocedural hemoglobin levels and 1-year major adverse cardiac events (MACE) in patients undergoing PCI.
Main Methods:
- A cohort of 2819 patients with available preprocedural Hb levels undergoing PCI were analyzed.
- Patients were categorized into nonanemic, mild, moderate, and severe anemia subgroups based on Hb levels.
- Major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), and revascularization, were tracked for 12 months.
Main Results:
- Severe anemia (Hb < 10 g/dL) was independently associated with a significantly increased risk of MACE (Hazard Ratio 4.623; P=0.004) after adjusting for multiple risk factors.
- Anemic patients were older, more frequently female, and less likely to smoke compared to nonanemic individuals.
- Patients with Hb < 10 g/dL exhibited the highest proportion of renal failure (56.7%).
Conclusions:
- The impact of anemia on 12-month MACE is particularly pronounced in patients with severe anemia (Hb < 10 g/dL).
- Preprocedural Hb levels, especially severe anemia, should be considered a critical factor in risk assessment for patients undergoing PCI.
Aim:
To evaluate the association between the preprocedural hemoglobin (Hb) level and 1 year major adverse cardiac event (MACE) in patients undergoing percutaneous coronary intervention (PCI).
Methods:
A total of 2819 patients (mean age 56.61 ± 10.37 years, 69% male) with available preprocedural Hb levels were included. Patients were followed up for 12 months. MACE included cardiac death, myocardial infarction (MI), target vessel revascularization and target lesion revascularization. MACE was compared across the different levels of Hb in nonanemic, mild, moderate, and severe anemia subgroups.
Results:
The preprocedural mean Hb level was 13.56 ± 1.67 g/dl. Anemic patients were older, more frequently women, and less likely to be cigarette smokers compared to the nonanemic group. Patients with Hb less than 10 mg/dl had the highest proportion of renal failure (56.7%) compared to 40.1% in moderate, 34.6% in mild, and 22.7% in nonanemic groups. In-hospital MI and death occurred in 8 (0.3%) and 2 (0.1%) of the nonanemic group, respectively, and 1 (0.3%) patient with mild anemia experienced MI. After 12 months the rate of total MACE was 3.4% in all the patients. After adjustment for age, sex, interaction between sex, and Hb level, smoking, hypertension, diabetes mellitus, and creatinine clearance, only severe anemia with Hb below 10 g/dl was associated with an increased risk of MACE (hazard ratio 4.623; 95% confidence interval 1.642-13.021; P = 0.004).
Conclusion:
The impact of anemia on the 12-month MACE was more prominent in patients with Hb below 10 mg/dl. Therefore, in patients with severe anemia listed for PCI, this level of Hb should be considered as a precaution.
Related Concept Videos
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:10Pre-Procedural Guidelines for Assessing Blood Pressure